Covidien Gains Barrett’s Esophagus Ablation Device Via Barrx Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Deal worth $325 million bolsters Covidien’s energy-based product offerings with Barrx Medical’s radiofrequency energy-based HaloFlex system for preventing esophageal cancer.